Therapeutics News and Research

RSS

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced that its Phase 2 safety study of CUBICIN (daptomycin for injection) in the treatment of prosthetic joint infections caused by certain Gram positive pathogens met its study objectives. This study was a first-of-its-kind randomized controlled Phase 2 trial studying anti-infective therapy in the setting of 2-stage surgery for the replacement of infected prosthetic hip or knee joints.

19 Jul 2010

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

ViroStatics, a US/Italian biopharmaceutical company developing innovative immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data from a randomized, dose-ranging trial of VS411, the Company's novel combination product for treating HIV/AIDS, during the XVII International AIDS Conference this week in Vienna, Austria.

19 Jul 2010

Epizyme publishes two new review papers on epigenetics

Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.

17 Jul 2010

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

Study results to help researchers better understand cancer genetics, improve treatment regimens

The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.

16 Jul 2010

Sumner M. Redstone donates $24M to Keck School of Medicine of USC to support cancer research

The Keck School of Medicine of the University of Southern California has announced a $24 million charitable gift from media executive and philanthropist Sumner M. Redstone. The multi-million dollar gift will support cancer research directed by renowned oncologist David Agus, M.D., professor of medicine at the Keck School of Medicine of USC and director of the USC Center for Applied Molecular Medicine and the USC Westside Prostate Cancer Center.

16 Jul 2010

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Cubist Pharmaceuticals, Inc. today announced results for the second quarter ended June 30, 2010.

16 Jul 2010

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.

16 Jul 2010

Cryo-Cell second-quarter consolidated revenues decrease to $4.3 million

Cryo-Cell International, Inc., one of the world's largest and most established family cord blood banks, today announced results for the second quarter ended May 31, 2010. Consolidated revenues for the second quarter of fiscal 2010 were $4.3 million compared to $4.7 million for the second quarter of fiscal 2009.

15 Jul 2010

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

Nitto Denko Corporation, Japan's leading diversified materials manufacturer and Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced the initiation of a collaboration and license agreement for the development of siRNA therapeutics for the treatment of fibrotic diseases.

15 Jul 2010

ALLOZYNE signs worldwide licensing agreement with The Scripps Research Institute

ALLOZYNE Inc. announced today the signing of a worldwide licensing agreement with The Scripps Research Institute. The agreement gives ALLOZYNE rights to a unique and powerful chemical reaction, developed by Nobel Laureate K. Barry Sharpless of Scripps Research, known as "Click chemistry." The novelty of this reaction comes from its ability to introduce two different molecular components and have them "click" together stably and irreversibly.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

PharmSource ranks Patheon as top global contract development and manufacturing organization

Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has been ranked as a top global contract development and manufacturing organization. PharmSource(R), a respected independent pharmaceutical research organization, recently published a study looking at the number of FDA new drug approvals (NDAs and BLAs) which were outsourced by sponsor companies and subsequently launched.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Efforts to raise disease awareness in the Philippines have increased the number of cases and patient pool available for hepatitis C treatment. Screening and detection efforts by the Red Cross as well as growing awareness in the Philippines have been largely responsible for the rise in the number of diagnosed cases. These campaigns have encouraged people, mostly from the urban areas, to opt for physical examinations that enable the detection of hepatitis C.

15 Jul 2010

Scientists awarded $2.3M grant to develop new treatments for drug addiction

A pair of scientists on the Florida campus of The Scripps Research Institute has been awarded a $2.3 million grant by the National Institutes of Health to conduct research relevant to developing new treatments for drug addiction.

15 Jul 2010

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

$Osseon receives notice of allowance for spinal vertebral compression fracture technology$

Osseon receives notice of allowance for spinal vertebral compression fracture technology

Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, today received a notice of allowance for its spinal vertebral compression fracture (VCF) technology. The company which was started in 2006 has thirteen additional patent applications pending in the United States and throughout the world for related spinal therapies and devices. The lead inventor for this inaugural patent is Dr. Y. King Liu, one of three founders of Osseon.

15 Jul 2010

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Aestus Therapeutics, Inc. announced today a collaboration agreement with Eisai Inc. on research and development of novel therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will entail pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.

15 Jul 2010

Therapeutics News and Research

Phase 2 CUBICIN study for prosthetic joint infections meets primary endpoint

ViroStatics to present VS411 Phase II dose-ranging trial data at International AIDS Conference in Vienna

Epizyme publishes two new review papers on epigenetics

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Study results to help researchers better understand cancer genetics, improve treatment regimens

Sumner M. Redstone donates $24M to Keck School of Medicine of USC to support cancer research

Cubist Pharmaceuticals total net revenues for second-quarter 2010 increase 29%

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Cryo-Cell second-quarter consolidated revenues decrease to $4.3 million

Nitto Denko, Quark collaborate to develop siRNA therapeutics for fibrotic diseases

ALLOZYNE signs worldwide licensing agreement with The Scripps Research Institute

NIH awards MacroGenics $9.8 million grant for three projects

PharmSource ranks Patheon as top global contract development and manufacturing organization

Activities of TAT fully consolidated into Geron

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

New drug launches for HCV in the Philippines to increase market earned revenues to $4.5 billion by 2017

Scientists awarded $2.3M grant to develop new treatments for drug addiction

Aduro BioTech announces issuance of two important patents

Osseon receives notice of allowance for spinal vertebral compression fracture technology

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News